TWI573593B - High oxygen water in the manufacture of a medicament for the treatment and / or prevention of hyperuricemia - Google Patents

Description

Use of hyperoxic water for the preparation of a medicament for the treatment and/or prevention of hyperuricemia

The present invention relates to a use of high-oxygen water for the treatment and/or prevention of hyperuricemia, in particular to a high-oxygen water having a relatively stable oxygen content and a small molecular group for preparing treatment and/or prevention. The use of uric acid drugs, which can treat and/or prevent hyperuricemia and related diseases, including hyperuricemia, gout, and other diseases caused by excessive uric acid.

Hyperuricemia refers to the extra-saturated urate that is usually caused by a super-high protein diet. In summary, uric acid is a metabolite of purine, which is metabolized in the liver to form uric acid, and finally uric acid is excreted in the urine.

As the concentration of uric acid increases in body fluids, it will over-saturate to form crystals. The uric acid crystals will deposit on the joints, induce granulocyte aggregation, produce inflammatory reactions, cause joint redness, swelling, heat and pain, and then form gouty arthritis or even Causes damage to the kidneys.

Gao Liang et al. published the article "Effects of Oxygen-enriched Water on Kidney Function after the Half-year Youth Movement in the Plateau" in the Journal of Clinical Military Medicine, Vol. 36, No. 1, February 2008, which claims to have confirmed that oxygen-enriched water can be improved. Damage to kidney tissue in a hypoxic environment has a protective effect on the kidneys in the high altitude hypoxia environment. In addition, the literature also pointed out that healthy young people who lived at high altitude for six months as subjects, those who exercised with oxygen-enriched water had lower uric acid value than those who did not drink oxygen-enriched water. In the data presented in this literature, the uric acid value of the control group was 397.7 μmol/L (about 6.68 mg/dL), and the uric acid value of the experimental group was 342.9 μmol/L (about 5.76 mg/dL). From this calculation, the uric acid value of the experimental group decreased by about 13.78%.

However, the aforementioned documents have the following points to note.

First of all, this document does not fully disclose how to carry out dissolved oxygen activation treatment to prepare oxygen-enriched water. The patent document cited in this document (Patent No.: 922412936) does not exist, so that those who have ordinary knowledge in the field cannot follow the literature. The teachings describe the preparation of oxygen-enriched water.

Secondly, the subjects in this literature were healthy young people living at high altitude for six months. The uric acid values of the control group and the experimental group were within the normal range (Note: uric acid value of normal human body, male is about 3.4~7.2 mg /dL, female is about 2.4~6.1 mg/dL), and the uric acid value is only about 13.78%. The experimental results can not fully show that its oxygen-rich water is indeed medically significant, especially for the average flat population. Uric acidemia, gout or other degenerative diseases.

Accordingly, there is a need to propose solutions to the problems encountered in prior art.

In view of the problems encountered in the prior art, the present invention discloses the use of high oxygen water for the preparation of a medicament for the treatment and/or prevention of hyperuricemia, wherein the oxygen content of the hyperoxic water changes with time. The amount is small and the stability is high. In addition, even if the high-oxygen water used in the present invention is placed under more severe conditions (for example, high temperature), it can maintain a higher dissolved oxygen value (for example, higher than 20 ppm or higher than 25 ppm), and after a certain period of time A relatively high oxygen content can still be maintained.

In one embodiment, the present invention provides a use of high oxygen water for preparing a medicament for treating and/or preventing hyperuricemia, wherein the high oxygen water has an oxygen content of not less than 20 ppm and is at a high level The initial oxygen content of the oxygen water is 100%, the oxygen content percentage (A) after the high oxygen water is allowed to stand for 30 minutes, and the oxygen content percentage (B) after the high oxygen water is allowed to stand for 180 minutes The difference (AB) between the two is less than 24%.

In a preferred embodiment, the aforementioned difference (A-B) is less than 20%, more preferably less than 15%, such as between 5% and 20%.

In one embodiment, the high oxygen water is measured by ¹⁷ O NMR ( ¹⁷ O NMR ) and the full width at half maximum is between 40 Hz and 80 Hz, preferably between 50 Hz and 70 Hz. Between 60 Hz and 70 Hz.

In one embodiment, the oxygenated water has an oxygen content of not less than 20 ppm, such as between 20 ppm and 50 ppm, such as between 25 ppm and 50 ppm. Further, in a preferred embodiment, the oxygenated water is still not less than 25 ppm after standing for 180 minutes.

In one embodiment, the oxygen content of the water-based high oxygen at 0 ^o C to 40 ^o C state is obtained for the measurement of high water, oxygen, for example, high-oxygen-based oxygen at 0 ^o C water 12 ^o C to the state of the measurement obtained, preferably for the oxygen-based high-oxygen water to 4 ^o C at 8 ^o C (e.g. 6 ^o C) obtained by measuring the amount under the state.

In a preferred embodiment, after the high oxygen water is heated from 10 ^o C to 40 ^o C, the oxygen content changes by less than 20%, preferably less than 10%.

In a preferred embodiment, after heating the high oxygen water from 10 ^o C to 40 ^o C, the oxygen content is not less than 25 ppm, preferably not less than 30 ppm.

In a preferred embodiment, after the high oxygen water is maintained at 30 ^o C to 40 ^o C for 120 minutes, the oxygen content changes by less than 30%, preferably less than 25%.

In a preferred embodiment, after the high oxygen water is maintained at 30 ^o C to 40 ^o C for 120 minutes, the oxygen content is not less than 20 ppm, preferably not less than 25 ppm.

In a preferred embodiment, the high-oxygen water can maintain a high oxygen content (for example, not less than 20 ppm, not less than 25 ppm, or not less than 30 ppm) at 30 ^o C to 40 ^o C. Up to 60 minutes.

In a preferred embodiment, the water under high oxygen conditions of about 37 ^o C can maintain a high oxygen content (e.g. less than 20 ppm, less than 25 ppm, or less than 30 ppm) of at least 60 minutes , 90 minutes or 120 minutes.

In a preferred embodiment, the water under high oxygen conditions of 40 ^o C higher than the oxygen content may be maintained less than 25 ppm.

In a preferred embodiment, after the high oxygen water is heated from an initial temperature of 5 ^o C to 10 ^o C to a temperature of 40 ^o C to 50 ^o C, the oxygen content changes by less than 20%, for example less than 15%. .

In a preferred embodiment, the oxygenate is maintained at an initial temperature of 5 ^o C to 10 ^o C to 50 ^o C, and the oxygen content is maintained at not less than 25 ppm, for example, not less than 30 ppm.

In one embodiment, the hyperoxic water contains only water, oxygen, and non-artificial additives.

In one embodiment, the aforementioned hyperoxic water can be prepared as a biocompatible composition comprising the aforementioned hyperoxic water and at least one biocompatible component.

For example, the aforementioned biocompatible composition may be a pharmaceutical composition or a beverage composition, and the biocompatible component may be an intravenous nutrient, a drug or a food additive, respectively.

In one embodiment, the hyperoxic water system is in the form of a pharmaceutical composition, and the pharmaceutical composition is formulated for oral, intravenous or intravenous infusion to provide to a recipient having hyperuricemia.

In one embodiment, the aforementioned pharmaceutical composition further comprises at least one drug for treating hyperuricemia.

In one embodiment, the method for preparing high-oxygen water includes the step of supplying oxygen to a water body, wherein the water body is maintained at 0 ^o C to 12 ^o C during the oxygen supply, to 50 cc. The flow of /min to 1000 cc/min continuously supplies oxygen to the water body, and the continuous oxygen supply time is not less than 30 minutes.

In one embodiment, the body of water is maintained at 4 ^o C to 8 ^o C during oxygen supply, such as 6 ^o C.

In one embodiment, the volume of the water body is between 1 liter and 15 liters, and/or the oxygen supply time is not less than 180 minutes, for example, about 210 minutes.

In one embodiment, during oxygen supply, oxygen is first supplied at a first flow rate until the oxygen content of the water body reaches between 20 ppm and 25 ppm, and then oxygen is supplied at a second flow rate, wherein the second flow rate Less than or equal to the first flow. For example, the first flow rate is no less than 50 cc/min and the second flow rate is no more than 1000 cc/min.

To make the features and functions of the present invention known to those of ordinary skill in the art, the following description and definitions of terms and terms mentioned in the specification and claims are generally described. Unless otherwise indicated, all technical and scientific terms used herein have the ordinary meaning of those of ordinary skill in the art, and in the case of a conflict, the definition of this specification shall prevail.

Certain theories mentioned and disclosed herein, whether correct or not, should not limit the scope of the invention in any way, as long as it can be achieved according to the disclosure of the present invention, Any particular theory or mechanism of action proposed by the present invention should be considered.

First, some parts of the text describe the components and technical features of the present invention by using "a", "an", "an" or the like. The description is only for convenience of expression and provides a general description of the technical features of the present invention. The meaning of sex. Therefore, unless otherwise indicated, the description is to be understood to include one or at least one

As used herein, the terms "comprising", "including", "having", "containing" or any other similar terms are open-ended transitional phrases, which are intended to cover non-exclusive inclusions. For example, a composition or article containing a plurality of elements is not limited to such elements as listed herein, but may also include other elements not specifically listed but which are generally inherent to the composition or article. In addition, the term "or" means an "or" inclusive unless it is specifically stated to the contrary, rather than an exclusive "or". For example, the condition "A or B" is satisfied in any of the following cases: A is true (or exists) and B is pseudo (or non-existent), A is pseudo (or non-existent) and B is true (or exists), A And B are both true (or exist). In addition, in this context, the interpretation of the terms "including", "including", "having" and "including" shall be deemed to have been specifically disclosed and covered by "consisting of" and "consisting essentially of" Or semi-closed conjunction.

In this context, the parameters such as temperature, flow rate, value, quantity or concentration, content, etc. of various components are usually expressed in the range of values or percentages. However, special attention should be paid to all features defined in the form of numerical ranges or percentage ranges or The conditions are only for the sake of simplicity and convenience. Accordingly, the recitation of ranges of values or ranges of percentages are to be construed as covering and specifically disclosing all possible sub-ranges and individual values, particularly integer values. For example, the description of the range of "1 to 8" should be regarded as having specifically disclosed all sub-ranges such as 1 to 7, 2 to 8, 2 to 6, 3 to 6, 4 to 8, 3 to 8, etc., in particular The sub-range defined by the integer value, and should be considered as an individual value such as 1, 2, 3, 4, 5, 6, 7, 8 and so on. Unless otherwise indicated, the foregoing explanations apply to all aspects of the present invention, whether broad or not.

Where the quantity, concentration or other value or parameter is expressed in terms of a range, a preferred range or a series of upper and lower limits, it should be understood that it is specifically disclosed herein that the upper or preferred value of the range is All ranges of lower or preferred values, whether or not they are disclosed separately. In addition, when a range of values is referred to herein, unless otherwise stated, the range shall include its endpoints and all integers and fractions within the range.

In this context, the values are understood to have the accuracy of the number of significant digits of the numerical value before the object of the invention can be achieved. For example, the number 40.0 should be understood to cover the range from 39.50 to 40.49.

In this context, those skilled in the art should understand the subgroups of all members of the Markusi group or the list of options for the use of Markush group or alternative terms to describe the features or examples of the present invention. Or any individual member may also be used to describe the invention. For example, if X is described as "selected from the group consisting of X _1, X ₂ and X ₃ the group consisting of," we have been fully described also represents a proposition and X is X ₁ X is X ₁ and / or X ₂ Proposition. Furthermore, those skilled in the art will be aware of any subgroup or individual member of all members of the Markusi group or option list for the use of the Markusi group or the alternative language to describe features or examples of the present invention. Combinations may also be used to describe the invention. Accordingly, for example, if X is described as "selected from a group consisting of X ₁ , X _{2 ,} and X ₃ ", and Y is described as "selected from Y ₁ , Y _{2 ,} and Y ₃ The group indicates that X is X ₁ or X ₂ or X ₃ and Y is Y ₁ or Y ₂ or Y ₃ .

Herein, if not otherwise specified, "water" refers to H ₂ O, which is present mainly in liquid form, and then also include other physical state, such as ice solid. In addition, as used herein, "water" means a substance mainly composed of H ₂ O molecules at normal temperature and pressure, which is usually used as a liquid medium and may contain other components or constituent units such as oxygen and trace elements (for example, calcium). The ion, magnesium ion, potassium ion, sodium ion, chloride ion, etc., and/or impurities are not limited thereto, and the other components or constituent units are often present due to natural factors during the formation of water, and are not artificially added. Therefore, in the present context, "water" includes not only a pure substance consisting purely of H ₂ O molecules, but also a composition or mixture containing a plurality of H ₂ O molecules as a carrier or medium and containing other components.

As used herein, the terms "composition" and "composition" are used interchangeably and are meant to mean an element consisting of one or a plurality of constituent units, components, compounds or substances. A "composition" is an artificially produced product or product, and the types, amounts, and physical forms of constituent units, components, compounds, or substances contained in the composition are usually limited, selected, or controlled by human intervention.

As used herein, unless otherwise specified, "oxygen-enriched" or "oxygenated" is used as an adjective to mean that a modified noun (such as water) is subjected to human intervention to cause oxygen, oxygen concentration or dissolution. The oxygen value is higher than the natural state or the state before the human intervention. If not specified, the terms "hyperoxidic water" and "oxygen-enriched water" may be used interchangeably. In addition, oxygen content, oxygen concentration, and dissolved oxygen value are collectively referred to as "oxygen saturation" to describe the amount or relative amount of oxygen present in a medium (eg, water) calculated in the same manner. The oxygen content, oxygen concentration or dissolved oxygen value of the medium is divided by the medium to achieve the highest oxygen content, oxygen concentration or dissolved oxygen value.

As used herein, "dissolved oxygen", "dissolved oxygen value", "dissolved oxygen", "dissolved oxygen", "oxygen content" and similar terms may be used interchangeably to mean oxygen per liter of medium (eg water). The degree is in mg/L or ppm. The measurement method of the dissolved oxygen value includes an electrochemical method, an optical method, a colorimetric method, a titration method, and the like. Since many instruments on the market can measure the dissolved oxygen value, it is not particularly described herein.

As used herein, "hyperuricemia" refers to any disease, condition, or condition in which serum levels of uric acid are too high (eg, men above 6.8 mg/dL, women above 6.0 mg/dL), including but not limited to gout , gouty arthritis, stroke, ischemic heart disease, renal dysfunction, uremia, urinary calculi, urate nephropathy, chronic kidney disease (CKD), hypoxanthine-guanine nucleoside transferase ( Hypoxanthine-guanine phosphoribosyltransferase, HGPRT) deficiency, hypertension and kidney stones.

As used herein, the term "biocompatible" means a substance that can be used in an organism (eg, a human) without causing serious adverse effects on the organism, and the term "biocompatible composition" is meant to encompass the present invention. A composition of oxygenated water wherein the hyperoxic water acts primarily as a medium or carrier for at least one biocompatible component.

As used herein, the term "pharmaceutical composition" refers to a composition comprising the hyperoxic water of the present invention for medical use, which typically includes another biocompatible component to provide or enhance a pharmaceutical effect, such as a parental nutrient (parenteral nutrition). ) or drugs.

As used herein, the term "beverage composition" means a composition comprising the hyperoxic water of the present invention and which is edible or drinkable, which generally comprises another biocompatible ingredient (ie, an edible ingredient such as a food additive) to facilitate It is sold, for example, but not limited to, preservatives, bactericides, antioxidants, nutritional additives, flavoring agents, sour agents, coloring agents, flavoring agents, sweeteners, viscosifiers, and emulsifiers.

As used herein, unless otherwise specified, the physicochemical properties are measured at atmospheric pressure (about 1 atm).

As used herein, unless otherwise specified, the physicochemical properties are measured at room temperature or ambient temperature (about 25 ^o C to about 27 ^o C).

As used herein, "resting" means placing hyperoxic water for a period of time in the absence of human intervention (eg, disturbance, vibration, or shaking), such as 5 minutes, 10 minutes, 30 minutes, 45, unless otherwise specified. Minutes, 60 minutes, 90 minutes, 120 minutes, 6 hours, 1 day, days, 1 week or weeks. The high oxygen water can be statically placed at a substantially constant temperature to maintain the temperature of the high oxygen water substantially fixed, for example, placed under adiabatic conditions, such as standing in a thermos flask or a cold bottle, or a high oxygen water. It is placed in an open environment where the temperature is approximately constant, and the ambient temperature is maintained by artificial heat control. In addition, the high-oxygen water can be placed in an environment where the temperature is not controlled, such as normal temperature conditions, such as 0 ^o C, 2 ^o C, 4 ^o C, 6 ^o C, 8 ^o C. , 10 ^o C, 12 ^o C, 15 ^o C, 20 ^o C, 30 ^o C, 40 ^o C, etc.) gradually rise or fall to normal temperature.

The following specific embodiments are merely exemplary in nature and are not intended to limit the invention. Further, the present disclosure is not limited by the foregoing description of the prior art or the invention or any of the embodiments described below.

Example: Preparation of high oxygen water

To prepare the high-oxygen water of the present invention, any water body may be subjected to oxygen supply (or "oxygenation" treatment under certain conditions, and the specific conditions are as described later.

In the present invention, the water body suitable for the oxygen treatment may be treated or untreated water, including but not limited to various commercially available bottled water, tap water, mineral water, purified water, distilled water, magnetized water, and electrolyzed water. Any kind of water body suitable for drinking, such as ionized water, ecological water, and reverse osmosis water. Unless otherwise specified, the scope of the water body includes a body of water mainly composed of water, and a body of water in which other components are present, such as a body of water having water as a main medium, such as various types of beverages.

The oxygen supply means as a source of oxygen supply may, for example, be disclosed in the case of the "Oxygen Manufacture Machine" of the new type of patent No. M439652 of the applicant (see also Chinese Utility Model Patent No. CN 202705029), the full text of which is This is incorporated herein by reference. In short, air compression can be performed by a conventional air compressor, and the compressed air is passed through a molecular sieve to adsorb nitrogen in the compressed air and output high-purity oxygen.

In order to cooperate with the method for producing high-oxygen water of the present invention, the oxygen supply means is preferably a continuous oxygen supply device, such as the aforementioned "oxygen production machine" patent, for continuous operation and continuous supply of oxygen. In addition, the oxygen supply means may also be a quantitative oxygen storage device, such as a conventional high pressure oxygen cylinder, which can continuously output oxygen for at least a certain period of time, for example, 30 minutes, 60 minutes, 120 minutes, 180 minutes, 210 minutes. Etc., wherein the specific flow rate applicable to the present invention is as described later.

Specifically, the oxygen output by the oxygen supply means may be pure oxygen or a high concentration of oxygen, for example, the concentration is higher than 80%, 85%, 90% or 95%, but not limited thereto.

During the oxygenation treatment, the water system is placed in a storage container, and the oxygen supply device continuously supplies oxygen to the water body in the storage container from below the water body, and the water body can also be placed in a large storage container. The water body is supplied from a larger storage container to a smaller storage container in communication therewith, and the oxygen supply device continuously supplies oxygen to the water body in the smaller storage container. During the oxygen addition, the storage container in which the water body is placed may be in an open state, a substantially sealed state, or a completely sealed state.

As a specific implementation example, please refer to the two cases of the new type of patent No. M438316 "High Dissolved Oxygen Water Dispenser" and M446884 "Molecular Molecular High Oxygen Water Drinking Machine" which have been approved by the applicant (other See Chinese Utility Model Patent No. 202820947 and No. 202932748, each of which is incorporated herein by reference in its entirety.

In order to facilitate the user to take the treated high-oxygen water, the oxygen supply device and the water storage container can be made into a water dispenser or a drinker, wherein the first water storage container can be a water supply device, which can supply water to The second body of water storage container, such as the cold water bladder of the water dispenser, continuously supplies oxygen to the body of water in the cold water bladder by the oxygen supply device. Thereby, the high oxygen water produced by the method for preparing high oxygen water according to the present invention can be conveniently taken by a user.

In a specific embodiment, the drinking machine includes a seat body and a water supply device and an oxygen manufacturing device disposed in the seat body, wherein the seat body is formed with a receiving space, and the bottom of the seat body is fixed with a support frame, and the top of the seat body The center is downwardly recessed with an opening for the inverted insertion of the water tank.

The water supply device has a base frame located in the accommodating space and positioned on the base body. The base frame is provided with a water storage tank. The center of the top seat installed above the storage space is provided with a water inlet passage which is aligned and communicates with the opening, and the center of the water inlet passage is There is a pusher head extending upwardly into the water storage bucket for the internal drinking water to flow into the storage space, and the top seat is further provided with a perforation through the upper and lower sides of the water inlet passage, and more than one connected water storage tank is provided in front of the base frame to send the drinking water The water head.

The oxygen manufacturing device is disposed in the accommodating space of the seat body, and the oxygen manufacturing device is provided with an air compressor, a solenoid valve, at least one oxygen concentrating tank and a storage tank above the support frame, and the electromagnetic valve is connected to the air compressor and the oxygen generating tank, And the oxygen storage tank is connected with the storage tank, and the storage tank is connected with a transfer tube extending upward from the upper side of the water storage tank, and the transport tube extends through the perforation of the top seat into the storage space, and then is disposed at the end of the transfer tube Aeration tube.

In an embodiment, the brewing machine further comprises a sterilization or disinfecting device, such as a UV lamp, which can be installed on the inner wall of the water storage tank or near the water outlet of the brewing machine, so as to ensure that the user can use the aseptic and Safe high oxygen water. Depending on the use of the high oxygen water, the type and amount of the sterilization or disinfection device may vary. For example, hyperoxic water for medical use typically has a higher level of sterilization requirements.

Although the prior art has disclosed various types of high-oxygen water and its preparation method, the inventors of the present invention have unexpectedly discovered that highly oxygenated water having excellent stability can be obtained under appropriate control of certain parameter conditions. Accordingly, the present invention discloses a method for preparing high-oxygen water, comprising the steps of supplying oxygen to a water body, wherein the water body is maintained at 0 ^o C to 12 ^o C during oxygen supply, Oxygen is supplied to the water at a flow rate of 50 cc/min to 1000 cc/min, and the oxygen supply time is not less than 30 minutes.

Specifically, the inventors of the present invention unexpectedly found that if the temperature, flow rate and time of the water in the process are properly controlled, it will be advantageous to improve the stability of the high oxygen water. The highly oxygenated water thus obtained can maintain a relatively small amount of oxygen under certain conditions.

In general, in the aforementioned preparation method, the volume of the water body is not particularly limited. Under mass manufacturing conditions, the volume of water can be hundreds of liters, thousands of liters or more. In the case of household use, if the above preparation method is operated or implemented in the form of a brewing machine, the volume of the brewing machine device is considered. Generally, the volume of the water body may be several tens of milliliters to several liters, for example, 100 milliliters, 200 milliliters, and 500 milliliters. Millimeter, 1 liter, 2 liters, 3 liters, 5 liters, 8 liters, 10 liters, 15 liters, etc., depending on the storage tank or cold water capacity of various types of drinking machines. In one embodiment, the volume of the water body is between 1 liter and 15 liters.

In the above preparation method, in terms of the treatment temperature, if the water body is maintained at 0 ^o C to 12 ^o C during the oxygen supply, a higher maximum dissolved oxygen value can be obtained. In particular, the inventors have unexpectedly found that an optimum dissolved oxygen effect can be obtained by maintaining the temperature at 4 ^o C to 8 ^o C, for example, the highest dissolved oxygen value can be about 60 ppm, 55 ppm or 50 ppm. In a preferred embodiment, the body of water is maintained at about 6 ^o C during oxygen supply.

In the foregoing preparation method, in terms of oxygen supply flow rate, the inventors have unexpectedly found that an excessively high oxygen flow rate does not contribute to the stability of the final high oxygen water, and may even be detrimental to the stability of high oxygen water under certain conditions. Sex. Conversely, the aforementioned preparation method supplies oxygen to a water body at a flow rate of 50 cc/min to 1000 cc/min to obtain a highly stable high oxygen water.

Taking the oxygen content of a typical water body of about 3 ppm to 5 ppm as an example, the inventors observed that the oxygen content of the water increased by about 20 ppm to 25 ppm before the supply of oxygen by the aforementioned preparation method. The oxygen content (ppm/min) increases with the flow of oxygen supplied. However, when the oxygen content of the water reaches about 20 ppm to 25 ppm, the oxygen content per minute is not significantly affected by oxygen. The effect of supply flow, even under certain conditions, if excessive flow (eg, above 1500 cc/min) is used for oxygen supply, it does not contribute to the stability of high oxygen water. Accordingly, the preparation method of the present invention supplies oxygen to a water body at a flow rate of 50 cc/min to 1000 cc/min, for example, a constant low flow rate for supplying oxygen at a constant time or at a full time, such as 50 cc/min, 100 cc. /min, 150 cc/min, 200 cc/min, 250 cc/min, 300 cc/min, 400 cc/min, 500 cc/min or 1000 cc/min, but not limited to this. Thereby, the oxygen-containing water obtained by the above method of the present invention has an oxygen content of at least 4 times or more than that of a general water body.

In an embodiment, oxygen may be supplied in different stages for oxygen supply. For example, during oxygen supply, oxygen is first supplied at a first flow rate until the oxygen content of the water reaches between 20 ppm and 25 ppm. Then, oxygen is supplied at a second flow rate, wherein the second flow rate is less than or equal to the first flow rate. For example, the first flow rate is no less than 50 cc/min and the second flow rate is no greater than 1000 cc/min.

In the foregoing preparation method, in terms of oxygen supply time, the inventors have unexpectedly found that, unlike the prior art, high-oxygen water is prepared in a short-time, high-flow, high-pressure manner, and the present invention is advantageous in that long-term continuous oxygen supply is advantageous. To improve the stability of high oxygen water. Therefore, in one embodiment, the oxygen supply time is not less than 30 minutes, for example, the oxygen supply time may be 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, or 240 minutes. In one embodiment, the oxygen supply time is from 60 minutes to 240 minutes. In one embodiment, when the oxygen content per minute of the water body is less than, for example, 0.01 ppm/min, it indicates that the oxygen content of the water body is approaching saturation, and the completed high oxygen water can be directly consumed or sealed for subsequent drinking. .

Accordingly, the preparation method of the present invention can perform oxygen supply treatment on water bodies of various volumes by controlling parameters such as water body temperature, oxygen supply flow rate, oxygen supply time, and the like to prepare high-oxygen water having excellent stability.

Example: Analysis of the properties of high oxygen water

In order to further confirm the physicochemical properties of the high-oxygen water prepared by the above method of the present invention, a certain volume of water (for example, about 3.7 liters, that is, 1 gallon) is poured into the cold water bladder of the aforementioned brewing machine to maintain the cooling pipeline. The temperature of the water body (for example, about 6 ^o C) is oxygenated at a specific flow rate (for example, about 200 cc/min) for a period of time (for example, about 210 minutes), and an embodiment of the present invention can be obtained after the oxygenation treatment is completed. High oxygen water.

540 μL of the sample was taken from the above-mentioned high-oxygen water, and 60 μL of D ₂ O (heavy water) was added and placed in a 5 mm NMR sample tube as an experimental group. Further, referring to the foregoing manner, a water body of the same source but not treated with oxygen was used as a control group.

The test ambient temperature is approximately room temperature and the relative humidity is approximately 50%.

¹⁷ O NMR ( ¹⁷ O NMR) analysis with 11.74 Tesla NMR using the following conditions: resonance frequency 67.768 MHz, sampling time 0.345 sec, data point 4096, spectral bandwidth 5940.4 Hz, 4096 scans, pulse excitation angle (flip) Angle)~67 ^o , relaxation delay 0.2 seconds, probe tuning (tune and match) normal, 25 ^o C pre-constant temperature >20 minutes, constant temperature flow rate >600 liters/min, " ¹⁷ O" The oxygen nucleus does not decouple the hydrogen nucleus (ie, the pulse-acquire pulse program), and the " ¹⁷ O dehydrogenation coupling" is to measure the oxygen nucleus while decoupling the hydrogen nucleus (ie, the inverse-gated pulse program).

The main data processing parameters for all NMR experiments were: no line broadening or any window function parameter, data point 8192, complex fast Fourier transform.

The results showed that the full width of the ¹⁷ O half-height of the experimental group was 64.16 Hz, the full width of the ¹⁷ O dehydrogenation coupling was 56.5 Hz; the full width of the ¹⁷ O half-height of the control group was 107.65 Hz, and the full width of the ¹⁷ O dehydrogenation coupling was 65.42 Hz.

In general, the smaller the water molecular group, the lower the full width value of the nuclear magnetic resonance half-height. It can be known from experimental data that the high-oxygen water prepared by the method of the present invention has a small water cluster size, which facilitates rapid penetration to In the body of the drinker, it can be quickly absorbed and promote metabolism, while providing a smoother and smoother taste.

In addition, it is believed that, in the high-oxygen water prepared by the foregoing embodiments of the present invention, approximately 5 to 6 water molecules are mutually hydrogen-bonded to form a molecular group, and each molecule is formed without any theoretical limitation. The number of hydrogen bonds in the group is about 5 to 10, thereby forming, for example, a cluster of 6 water molecules, 8 hydrogen bonds, or a column forming, for example, 6 water molecules and 9 hydrogen bonds ( The prism is a molecular group, and oxygen is coated in the three-dimensional structure of the molecular group, thereby achieving a relatively stable oxygen content.

Example: Measurement of the highest oxygen content of high oxygen water

The commercially available Yue's bottled mineral water and topped bottled mineral water are respectively treated as the water to be treated and the water to be treated. The original oxygen content before oxygenation is 3.7 ppm and 3.5 ppm, respectively. Pour a certain volume (about 1 gallon) of the above water body into the cold water bladder of the brewing machine of the foregoing embodiment, to maintain the temperature of the water body (about 4 ^o C to 8 ^o C), and to a certain flow rate. (Approx. 200 cc/min) was treated with oxygen. During the treatment, about 200 ml of water was periodically discharged and its oxygen content was measured at room temperature with a dissolved oxygen tester WTW Oxi3210 and a CellOx 325 electrode. Experiments have shown that the water to be treated reaches a maximum oxygen content of about 38.5 ppm after about 208 minutes of oxygen treatment, and the water to be treated reaches a maximum oxygen content of about 37.8 ppm after about 220 minutes of oxygen treatment.

Example: Stability Analysis of High Oxygen Water (I)

The water body to be treated and the water body to be treated are subjected to oxygenation treatment in the manner described in the foregoing embodiment to obtain high-oxygen water and high-oxygen water two, and output about 200 ml respectively at room temperature to be placed in an open environment. The oxygen content of high-oxygen water and high-oxygen water 2 was measured periodically with time. The results are shown in Table 1 below. Table I         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> Measurement time (hr) </td><td> Hyperoxic water-oxygen ( Ppm) </td><td> Percentage of relative oxygen content (%) </td><td> Oxygen content of high oxygen water (ppm) </td><td> Percentage of relative oxygen content (%) < /td></tr><tr><td> 0 </td><td> 37.9 </td><td> 100 </td><td> 38.6 </td><td> 100 </td> </tr><tr><td> 0.5 </td><td> 30.3 </td><td> 79.95 </td><td> 31.0 </td><td> 80.31 </td></tr ><tr><td> 1 </td><td> 28.9 </td><td> 76.25 </td><td> 29.2 </td><td> 75.65 </td></tr><tr ><td> 1.5 </td><td> 27.3 </td><td> 72.03 </td><td> 27.8 </td><td> 72.02 </td></tr><tr><td > 2 </td><td> 26.9 </td><td> 70.98 </td><td> 26.4 </td><td> 68.39 </td></tr><tr><td> 2.5 < /td><td> 26.7 </td><td> 70.45 </td><td> 25.7 </td><td> 66.58 </td></tr><tr><td> 3 </td> <td> 25.7 </td><td> 67.81 </td><td> 25.0 </td><td> 64.77 </td></tr><tr><td> 3.5 </td><td> 23.8 </td><td> 62.80 </td><td> 24.2 </td><td> 62.69 </td></tr><tr><td> 4 </td><td> 21.6 </ Td><td> 56.99 </td><td> 21.9 </td><td> 56.74 </td></tr><tr> <td> 4.5 </td><td> 21.3 </td><td> 56.20 </td><td> 20.7 </td><td> 53.63 </td></tr><tr><td> 5 </td><td> 21.0 </td><td> 55.41 </td><td> 20.1 </td><td> 52.07 </td></tr><tr><td> 5.5 </ Td><td> 20.7 </td><td> 54.62 </td><td> 19.7 </td><td> 51.04 </td></tr><tr><td> 6 </td>< Td> 20.5 </td><td> 54.09 </td><td> 19.2 </td><td> 49.74 </td></tr><tr><td> 6.5 </td><td> 20.2 </td><td> 53.30 </td><td> 19.0 </td><td> 49.22 </td></tr><tr><td> 7 </td><td> 20.2 </td ><td> 53.30 </td><td> 18.9 </td><td> 48.96 </td></tr><tr><td> 7.5 </td><td> 20.1 </td><td > 53.03 </td><td> 18.7 </td><td> 48.45 </td></tr><tr><td> 8 </td><td> 20.1 </td><td> 53.03 < /td><td> 18.6 </td><td> 48.19 </td></tr><tr><td> 8.5 </td><td> 20.0 </td><td> 52.77 </td> <td> 18.5 </td><td> 47.93 </td></tr><tr><td> 9 </td><td> 19.9 </td><td> 52.51 </td><td> 18.4 </td><td> 47.67 </td></tr><tr><td> 9.5 </td><td> 19.8 </td><td> 52.24 </td><td> 18.3 </ Td><td> 47.41 </td></tr><tr><td> 10 </td><td> 19.7 </td><td> 51.98 </td><td> 18.2 </td>< Td> 47.15 </td> </tr><tr><td> 10.5 </td><td> 19.7 </td><td> 51.98 </td><td> 18.1 </td><td> 46.89 </td></tr ><tr><td> 11 </td><td> 19.6 </td><td> 51.72 </td><td> 18.0 </td><td> 46.63 </td></tr><tr ><td> 11.5 </td><td> 19.6 </td><td> 51.72 </td><td> 18.0 </td><td> 46.63 </td></tr><tr><td > 12 </td><td> 19.5 </td><td> 51.45 </td><td> 17.9 </td><td> 46.37 </td></tr><tr><td> 12.5 < /td><td> 19.5 </td><td> 51.45 </td><td> 17.9 </td><td> 46.37 </td></tr><tr><td> 13 </td> <td> 19.4 </td><td> 51.19 </td><td> 17.8 </td><td> 46.11 </td></tr><tr><td> 13.5 </td><td> 19.4 </td><td> 51.19 </td><td> 17.7 </td><td> 45.85 </td></tr><tr><td> 14 </td><td> 19.3 </ Td><td> 50.92 </td><td> 17.7 </td><td> 45.85 </td></tr><tr><td> 14.5 </td><td> 19.3 </td>< Td> 50.92 </td><td> 17.6 </td><td> 45.60 </td></tr><tr><td> 15 </td><td> 19.2 </td><td> 50.66 </td><td> 17.6 </td><td> 45.60 </td></tr><tr><td> 15.5 </td><td> 19.2 </td><td> 50.66 </td ><td> 17.5 </td><td> 45.34 </td></tr><tr><td> 16 </td><td> 19.1 </td><td> 50.40 </td><td > 17.5 < /td><td> 45.34 </td></tr><tr><td> 16.5 </td><td> 19.1 </td><td> 50.40 </td><td> 17.4 </td> <td> 45.08 </td></tr><tr><td> 17 </td><td> 19.0 </td><td> 50.13 </td><td> 17.4 </td><td> 45.08 </td></tr><tr><td> 17.5 </td><td> 19.0 </td><td> 50.13 </td><td> 17.3 </td><td> 44.82 </ Td></tr><tr><td> 18 </td><td> 18.9 </td><td> 49.87 </td><td> 17.4 </td><td> 45.08 </td>< /tr><tr><td> 18.5 </td><td> 18.9 </td><td> 49.87 </td><td> 17.3 </td><td> 44.82 </td></tr> <tr><td> 19 </td><td> 18.9 </td><td> 49.87 </td><td> 17.2 </td><td> 44.56 </td></tr><tr> <td> 19.5 </td><td> 18.8 </td><td> 49.60 </td><td> 17.2 </td><td> 44.56 </td></tr><tr><td> 20 </td><td> 18.8 </td><td> 49.60 </td><td> 17.1 </td><td> 44.30 </td></tr><tr><td> 20.5 </ Td><td> 18.8 </td><td> 49.60 </td><td> 17.1 </td><td> 44.30 </td></tr><tr><td> 21 </td>< Td> 18.7 </td><td> 49.34 </td><td> 17.0 </td><td> 44.04 </td></tr><tr><td> 21.5 </td><td> 18.7 </td><td> 49.34 </td><td> 17.0 </td><td> 44.04 </td></tr><tr><td> 22 </td><td> 18.7 </td ><td> 49 .34 </td><td> 16.9 </td><td> 43.78 </td></tr><tr><td> 22.5 </td><td> 18.6 </td><td> 49.08 < /td><td> 16.9 </td><td> 43.78 </td></tr><tr><td> 23 </td><td> 18.6 </td><td> 49.08 </td> <td> 16.9 </td><td> 43.78 </td></tr><tr><td> 23.5 </td><td> 18.6 </td><td> 49.08 </td><td> 16.8 </td><td> 43.52 </td></tr><tr><td> 24 </td><td> 18.5 </td><td> 48.81 </td><td> 16.8 </ Td><td> 43.52 </td></tr></TBODY></TABLE>

It can be found from the above table that the oxygen content of the high-oxygen water is reduced within 30 minutes after the preparation is completed. It is presumed that the dissolved oxygen state has not stabilized during this period, but it is more stable afterwards. The oxygen content reduction decreases with time. In addition, it can be found that the initial oxygen content (37.9 ppm) of the high-oxygen water and the initial oxygen content (38.6 ppm) of the high-oxygen water two are regarded as 100%, respectively, even in an open environment and at room temperature. The percentage of oxygen content after the high-oxygen water was allowed to stand for 30 minutes (79.95% and 80.31%, respectively) minus the percentage of oxygen content after the high-oxygen water was allowed to stand for 180 minutes (67.81% and 64.77%, respectively) The oxygen content was 12.14% and 15.54%, respectively, and the oxygen content after standing for 180 minutes was still greater than or equal to 25 ppm, indicating that the high oxygen water of the present invention has high stability.

Example: Stability Analysis of High Oxygen Water (II)

Prepare high-oxygen water and high-oxygen water two in the manner of the foregoing examples, and heat them to 10 ^o C, 15 ^o C, 20 ^o C, 25 ^o C and 30 ^o C to 40 ^o C, respectively, and measure their oxygen content. The results are shown in Table 2 below. Table 2 <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Temperature (^oC) </td><td> High oxygen water-oxygen content (ppm) </td><td> Percent oxygen content (%) </td><td> High oxygen water oxygen content (ppm) </td><td> Relative Oxygen percentage (%) </td></tr><tr><td> 10 </td><td> 34.9 </td><td> 100 </td><td> 37.0 </td><td> 100 </td></tr><tr><td> 15 </td><td> 35.9 </td><td> 102.87 </td><td> 37.0 </td><td> 100 </td></tr><tr><td> 20 </td><td> 37.0 </td><td> 106.02 </td><td> 38.5 </td><td> 104.05 </ Td></tr><tr><td> 25 </td><td> 36.3 </td><td> 104.01 </td><td> 40.6 </td><td> 109.73 </td></tr><tr><td> 30 </td><td> 33.7 </td><td> 96.56 </td><td> 30.9 </td><td> 83.51 </td></tr><tr><td> 31 </td><td> 33.7 </td><td> 96.56 </td><td> 29.8 </td><td> 80.54 </td></tr><tr><td> 32 </td><td> 33.4 </td><td> 95.70 </td><td> 29.8 </td><td> 80.54 </td></tr><tr><td> 33 </td><td> 33.2 </td><td> 95.13 </td><td> 29.8 </td><td> 80.54 </td></tr><tr><td> 34 </ Td><td> 33.5 </td><td> 95.99 </td><td> 29.8 </td><td> 80.54 </td></tr><tr><td> 35 </td><td> 33.3 </td><td> 95.42 </td><td> 29.9 </td><td> 80.81 </td ></tr><tr><td> 36 </td><td> 33.1 </td><td> 94.84 </td><td> 29.9 </td><td> 80.81 </td></ Tr><tr><td> 37 </td><td> 32.7 </td><td> 93.70 </td><td> 29.9 </td><td> 80.81 </td></tr><Tr><td> 38 </td><td> 32.6 </td><td> 93.41 </td><td> 29.9 </td><td> 80.81 </td></tr><tr><Td> 39 </td><td> 32.4 </td><td> 92.84 </td><td> 29.8 </td><td> 80.54 </td></tr><tr><td> 40 </td><td> 32.4 </td><td> 92.84 </td><td> 29.9 </td><td> 80.81 </td></tr></TBODY></TABLE>

In Table 2, it can be observed that there is an increase in oxygen content in the initial stage of preparation of high-oxygen water to the initial heating stage (15 ^o C to 25 ^o C), which is supposed to be due to the fact that the preparation of high-oxygen water has not yet reached stability. Due to the status. After entering a steady state, it can be found that the oxygen content of the high oxygen water tends to be stable. For hyperoxic water, it can be found that after heating from 10 ^o C to 40 ^o C, the oxygen content changes by less than 10%, and the oxygen content is maintained above 30 ppm during heating; for high oxygen water For example, it can be found that after heating from 10 ^o C to 40 ^o C, the oxygen content changes by less than 20% and the oxygen content is maintained at about 30 ppm.

Example: Stability Analysis of High Oxygen Water (III)

Prepare high-oxygen water- and high-oxygen water two in the manner of the foregoing examples, and heat them to 37 ^o C, 35 ^o C, 30 ^o C from the initial temperature and maintain the temperature at 30, 60, 90, respectively. The oxygen content was measured after 120 minutes and the results are shown in Table 3 (37 ^o C), Table 4 (35 ^o C) and Table 5 (30 ^o C), respectively. Table 3 <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> high oxygen water-oxygen content (ppm) </td><td> relative oxygen content percentage (%) </td><td> measurement time point (min </td><td> temperature (^oC) </td><td> high oxygen dioxide oxygen content (ppm) </td><td> relative oxygen content ( %) </td></tr><tr><td> Just completed </td><td> 8.9 </td><td> 37.4 </td><td> X </td><td> Just finished preparation</td><td> 5.7 </td><td> 34.9 </td><td> X </td></tr><tr><td> 0 </td><td> 37.0 </td><td> 33.8 </td><td> 100 </td><td> 0 </td><td> 37.0 </td><td> 32.7 </td><td> 100 </ Td></tr><tr><td> 30 </td><td> 37.2 </td><td> 31.6 </td><td> 93.49 </td><td> 30 </td><Td> 37.2 </td><td> 30.4 </td><td> 92.97 </td></tr><tr><td> 60 </td><td> 37.1 </td><td> 29.8 </td><td> 88.17 </td><td> 60 </td><td> 37.1 </td><td> 28.9 </td><td> 88.38 </td></tr><tr ><td> 90 </td><td> 37.0 </td><td> 27.7 </td><td> 81.95 </td><td> 90 </td><td> 37.3 </td><Td> 27.6 </td><td> 84.40 </td></tr><tr><td> 120 </td><td> 37.1 </td><td> 26.4 </td><td> 78.11 </td><td> 120 </td><td> 36.8 </td><td> 25.8 </ Td><td> 78.90 </td></tr></TBODY></TABLE> Table 4 <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> High oxygen water-oxygen content (ppm) </td><Td> Percent relative oxygen content (%) </td><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> High Oxygen water oxygen content (ppm) </td><td> Percent oxygen content (%) </td></tr><tr><td> Just completed preparation</td><td> 8.9 </td><td> 37.1 </td><td> X </td><td> Just completed </td><td> 8.7 </td><td> 34.9 </td><td> X </td></tr><tr><td> 0 </td><td> 34.8 </td><td> 34.1 </td><td> 100 </td><td> 0 </td><td> 35.2 </td><td> 33.1 </td><td> 100 </td></tr><tr><td> 30 </td><td> 35.2 </td><td> 32.9 </td><td> 96.48 </td><td> 30 </td><td> 34.9 </td><td> 30.9 </td><td> 93.35 </td></tr><Tr><td> 60 </td><td> 35.3 </td><td> 31.6 </td><td> 92.67 </td><td> 60 </td><td> 35.1 </td><td> 29.5 </td><td> 89.12 </td></tr><tr><td> 90 </td><td> 35.2 </td><td> 29.8 </td><td> 87.39 </td><td> 90 </td><td> 35.2 </td><td> 28.1 </td><td> 84.89 </td></tr><tr><td> 120 </td><td> 35.1 </td><td> 27.9 </td><td> 81.82 </td><td> 120 </td><td> 34.8 </td><td> 26.8 </td><td> 80.97 </td></tr></TBODY></TABLE> Table 5 <TABLE border= "1"borderColor="#000000"width="85%"><TBODY><tr><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> high oxygen water-oxygen content (ppm) </td><td> relative oxygen content percentage (%) </td><td> measurement time point (min) </td><Td> temperature (^oC) </td><td> high oxygen dioxide oxygen content (ppm) </td><td> relative oxygen content percentage (%) </td></tr><tr><td> Just completed </td><td> 8.9 </td><td> 37.4 </td><td> X </td><td> Just finished </td ><td> 8.6 </td><td> 34.7 </td><td> X </td></tr><tr><td> 0 </td><td> 30.1 </td><td > 36.9 </td><td> 100 </td><td> 0 </td><td> 30.3 </td><td> 33.4 </td><td> 100 </td></tr><tr><td> 30 </td><td> 29.8 </td><td> 34.2 </td><td> 92.68 </td><td> 30 </td><td> 29.8 </td ><td> 32.1 </td><td> 96.11 </td></tr><tr ><td> 60 </td><td> 30.2 </td><td> 33.1 </td><td> 89.70 </td><td> 60 </td><td> 30.1 </td><Td> 30.9 </td><td> 92.51 </td></tr><tr><td> 90 </td><td> 30.1 </td><td> 30.4 </td><td> 82.38 </td><td> 90 </td><td> 30.2 </td><td> 29.1 </td><td> 87.13 </td></tr><tr><td> 120 </td ><td> 29.7 </td><td> 29.1 </td><td> 78.86 </td><td> 120 </td><td> 29.9 </td><td> 27.9 </td><Td> 83.53 </td></tr></TBODY></TABLE>

From the data in Tables 3 to 5, it can be observed that the oxygen-containing water of the present invention has a change in oxygen content of less than 30%, preferably less than 25, after being maintained at 30 ^o C to 40 ^o C for 120 minutes. %, more preferably less than 20%. Further, the high-oxygen water of the present invention has an oxygen content of not less than 20 ppm, preferably not less than 25 ppm, for a period of 120 minutes at 30 ^o C to 40 ^o C. On the other hand, the high-oxygen water of the present invention under conditions of 30 ^o C to 40 ^o C of less than 20 ppm oxygen can be maintained for at least 60 minutes and more preferably in the system at about 37 ^o C of Maintain oxygen levels of not less than 25 ppm for at least 120 minutes.

Since the temperature of the general human body is about 37 ^o C, it can be seen from the above data that the hyperoxic water of the present invention maintains a relatively high oxygen content under normal human body temperature conditions, and can maintain oxygen content at 37 ^o C. Less than 25 ppm for at least 120 minutes, this time is enough to allow high-oxygen water to circulate in the body for a long time while still maintaining high oxygen content, which is beneficial to increase the oxygen content of various parts of the body.

Further, the commercially available natural beauty care and living one hundred high-oxygen water of high oxygen water HOPPER O ₂ were used as Comparative Examples and a Comparative Example II were heated to an initial temperature of from ^{37 o C, 35 o C,} 30 o C and maintained substantially At this temperature, the oxygen content was measured after 30, 60, 90, and 120 minutes, and the results are shown in Table 6 (37 ^o C), Table 7 (35 ^o C), and Table 8 (30 ^o C), respectively. Show. Table 6 <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> Comparative Example 1 Oxygen Content (ppm) </td><td> Relative Oxygen Content Percent (%) </td><td> Measurement Time (min) </td><td> Temperature (^oC) </td><td> Comparative Example II Oxygen Content (ppm) </td><td> Percentage of Relative Oxygen Content (%) </td></tr><tr><td> When opening the bottle</td><td> 26.6 </td><td> 23.5 </td><td> X </td><td> Open the bottle Time </td><td> 25.4 </td><td> 17.2 </td><td> X </td></tr><tr><td> 0 </td><td> 37.0 </ Td><td> 21.1 </td><td> 100 </td><td> 0 </td><td> 37.0 </td><td> 13.3 </td><td> 100 </td></tr><tr><td> 30 </td><td> 37.3 </td><td> 19.4 </td><td> 91.94 </td><td> 30 </td><td> 37.2 </td><td> 11.1 </td><td> 83.46 </td></tr><tr><td> 60 </td><td> 37.1 </td><td> 16.5 </ Td><td> 78.20 </td><td> 60 </td><td> 37.3 </td><td> 10.2 </td><td> 76.69 </td></tr><tr><Td> 90 </td><td> 36.9 </td><td> 14.9 </td><td> 70.62 </td><td> 90 </td><td> 36.9 </td><td> 8.9 </td><td> 66.92 </td></tr><tr><td> 120 </td><td> 3 7.3 </td><td> 12.1 </td><td> 57.35 </td><td> 120 </td><td> 37.2 </td><td> 7.8 </td><td> 58.65 </td></tr></TBODY></TABLE> Table 7 <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Measurement time point ( Min) </td><td> Temperature (^oC) </td><td> Comparative Example 1 Oxygen Content (ppm) </td><td> Relative Oxygen Content Percentage ( %) </td><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> Comparative Example 2 Oxygen content (ppm) </td><td> Percentage of relative oxygen content (%) </td></tr><tr><td> When opening the bottle</td><td> 26.6 </td><td> 23.4 </ Td><td> X </td><td> When opening the bottle</td><td> 25.4 </td><td> 17.1 </td><td> X </td></tr><tr ><td> 0 </td><td> 35.1 </td><td> 21.3 </td><td> 100 </td><td> 0 </td><td> 35.1 </td><Td> 13.2 </td><td> 100 </td></tr><tr><td> 30 </td><td> 34.8 </td><td> 19.1 </td><td> 89.67 </td><td> 30 </td><td> 34.8 </td><td> 11.2 </td><td> 84.85 </td></tr><tr><td> 60 </td ><td> 34.9 </td><td> 16.9 </td><td> 79.34 </td><td> 60 </td><td> 34.9 </td><td> 10.3 </td><Td> 78.03 </td></tr><tr><td> 90 </td><td> 35.3 </t d><td> 15.1 </td><td> 70.89 </td><td> 90 </td><td> 35.3 </td><td> 9.3 </td><td> 70.45 </td></tr><tr><td> 120 </td><td> 35.2 </td><td> 13.2 </td><td> 61.97 </td><td> 120 </td><td> 35.2 </td><td> 8.2 </td><td> 62.12 </td></tr></TBODY></TABLE> Table 8 <TABLE border="1"borderColor="#000000" width= "85%"><TBODY><tr><td> Measurement time point (min) </td><td> Temperature (^oC) </td><td> Comparative example 1 Oxygen (ppm) </td><td> Percentage of relative oxygen content (%) </td><td> Measurement time point (min) </td><td> Temperature (^o C) </td><td> Comparative Example II Oxygen Content (ppm) </td><td> Relative Oxygen Content Percent (%) </td></tr><tr><td> When opening the bottle </td><td> 26.6 </td><td> 23.6 </td><td> X </td><td> When opening the bottle</td><td> 25.4 </td><td> 17.3 </td><td> X </td></tr><tr><td> 0 </td><td> 30.3 </td><td> 21.9 </td><td> 100 </td ><td> 0 </td><td> 29.8 </td><td> 13.4 </td><td> 100 </td></tr><tr><td> 30 </td><td > 29.8 </td><td> 19.7 </td><td> 89.95 </td><td> 30 </td><td> 30.1 </td><td> 11.6 </td><td> 86.57 </td></tr><tr><td> 60 </td><td> 30.1 </td><td> 17.6 </td><td> 80.37 </td><td> 60 </td><td> 30.2 </td><td> 10.5 </td><td> 78.36 </td></tr><Tr><td> 90 </td><td> 30.2 </td><td> 16.5 </td><td> 75.34 </td><td> 90 </td><td> 29.9 </td><td> 9.6 </td><td> 71.64 </td></tr><tr><td> 120 </td><td> 29.7 </td><td> 14.3 </td><td> 65.30 </td><td> 120 </td><td> 30.1 </td><td> 8.7 </td><td> 64.93 </td></tr></TBODY></TABLE>

Comparing the examples of the invention and the comparative examples of Tables 6 to 8 in Tables 3 to 5, it can be easily found that the high oxygen water of the present invention is placed at a relatively high temperature (above 30 ^o C), after 120 minutes, The oxygen content is still maintained, and the oxygen content is preferably less than 25%, more preferably less than 20%, and the oxygen content is still higher than 20 ppm, more preferably higher than 25 ppm after 120 minutes. On the other hand, the high-oxygen water of the comparative example was placed at a relatively high temperature (above 30 ^o C), and after 120 minutes, it could not maintain a high oxygen content, and the oxygen content decreased by about 35% to 43. %, and the oxygen content is less than 15 ppm.

Example: Stability Analysis of High Oxygen Water (IV)

High-oxygen water- and high-oxygen water two were prepared in the manner of the foregoing examples, and the initial temperature of about 8 ^o C was separately heated to about 50 ^o C, and the oxygen content change was continuously observed during the period. The results are shown in Table IX. Table IX <TABLE border="1"borderColor="#000000"width="85%"><TBODY><tr><td> Temperature (^oC) </td><td> High oxygen water-oxygen content (ppm) </td><td> Percent oxygen content (%) </td><td> High oxygen water oxygen content (ppm) </td><td> Relative Percent oxygen content (%) </td></tr><tr><td> 8.4 </td><td> 34.9 </td><td> 100 </td><td> 37.1 </td><td> 100 </td></tr><tr><td> 10 </td><td> 34.9 </td><td> 100 </td><td> 37.0 </td><td> 99.73 </td></tr><tr><td> 11 </td><td> 34.9 </td><td> 100 </td><td> 36.3 </td><td> 97.84 </ Td></tr><tr><td> 12 </td><td> 35.5 </td><td> 101.72 </td><td> 36.0 </td><td> 97.04 </td></tr><tr><td> 13 </td><td> 35.5 </td><td> 101.72 </td><td> 36.5 </td><td> 98.38 </td></tr><tr><td> 14 </td><td> 35.6 </td><td> 102.01 </td><td> 36.9 </td><td> 99.46 </td></tr><tr><td> 15 </td><td> 35.9 </td><td> 102.87 </td><td> 37.0 </td><td> 99.73 </td></tr><tr><td> 16 </td><td> 36.1 </td><td> 103.44 </td><td> 37.2 </td><td> 100.27 </td></tr><tr><td> 17 </ Td><td> 36.4 </td><td> 104.30 </td><td> 37.6 </td><td> 101. 35 </td></tr><tr><td> 18 </td><td> 36.9 </td><td> 105.73 </td><td> 38.0 </td><td> 102.43 </ Td></tr><tr><td> 19 </td><td> 37.2 </td><td> 106.59 </td><td> 38.5 </td><td> 103.77 </td></tr><tr><td> 20 </td><td> 37.0 </td><td> 106.02 </td><td> 38.5 </td><td> 103.77 </td></tr><tr><td> 21 </td><td> 37.2 </td><td> 106.59 </td><td> 39.2 </td><td> 105.66 </td></tr><tr><td> 22 </td><td> 37.2 </td><td> 106.59 </td><td> 39.6 </td><td> 106.74 </td></tr><tr><td> 23 </td><td> 37.0 </td><td> 106.02 </td><td> 39.8 </td><td> 107.28 </td></tr><tr><td> 24 </ Td><td> 36.6 </td><td> 104.87 </td><td> 40.4 </td><td> 108.89 </td></tr><tr><td> 25 </td><Td> 36.3 </td><td> 104.01 </td><td> 40.6 </td><td> 109.43 </td></tr><tr><td> 26 </td><td> 35.2 </td><td> 100.86 </td><td> 40.4 </td><td> 108.89 </td></tr><tr><td> 27 </td><td> 34.3 </td ><td> 98.28 </td><td> 40.7 </td><td> 109.70 </td></tr><tr><td> 28 </td><td> 33.9 </td><td > 97.13 </td><td> 38.6 </td><td> 104.04 </td></tr><tr><td> 29 </td><td> 33.9 </td><td> 97.13 </td><td> 37.7 </td><td> 101.62 </td></tr><tr><td> 30 </td><td> 33.7 </td><td> 96.56 </td ><td> 36.9 </td><td> 99.46 </td></tr><tr><td> 31 </td><td> 33.7 </td><td> 96.56 </td><td > 36.1 </td><td> 97.30 </td></tr><tr><td> 32 </td><td> 33.4 </td><td> 95.70 </td><td> 35.4 </td><td> 95.42 </td></tr><tr><td> 33 </td><td> 33.2 </td><td> 95.13 </td><td> 34.9 </td><td> 94.07 </td></tr><tr><td> 34 </td><td> 33.5 </td><td> 95.99 </td><td> 34.6 </td><td> 93.26 </td></tr><tr><td> 35 </td><td> 33.3 </td><td> 95.42 </td><td> 34.3 </td><td> 92.45 </ Td></tr><tr><td> 36 </td><td> 33.1 </td><td> 94.84 </td><td> 34.1 </td><td> 91.91 </td></tr><tr><td> 37 </td><td> 32.7 </td><td> 93.70 </td><td> 33.8 </td><td> 91.11 </td></tr><tr><td> 38 </td><td> 32.6 </td><td> 93.41 </td><td> 33.5 </td><td> 90.30 </td></tr><tr><td> 39 </td><td> 32.4 </td><td> 92.84 </td><td> 33.3 </td><td> 89.76 </td></tr><tr><td> 40 </td><td> 32.4 </td><td> 92.84 </td><td> 33.2 </td><td> 89.49 </td></tr><tr><td> 41 </ Td><td> 32.2 </td><t d> 92.26 </td><td> 33.1 </td><td> 89.22 </td></tr><tr><td> 42 </td><td> 32.1 </td><td> 91.98 </td><td> 32.8 </td><td> 88.41 </td></tr><tr><td> 43 </td><td> 32.0 </td><td> 91.69 </td ><td> 32.7 </td><td> 88.14 </td></tr><tr><td> 44 </td><td> 32.0 </td><td> 91.69 </td><td > 32.5 </td><td> 87.60 </td></tr><tr><td> 45 </td><td> 32.1 </td><td> 91.98 </td><td> 32.5 </td><td> 87.60 </td></tr><tr><td> 46 </td><td> 31.9 </td><td> 91.40 </td><td> 32.4 </td><td> 87.33 </td></tr><tr><td> 47 </td><td> 31.7 </td><td> 90.83 </td><td> 32.4 </td><td> 87.33 </td></tr><tr><td> 48 </td><td> 31.6 </td><td> 90.54 </td><td> 32.2 </td><td> 86.79 </ Td></tr><tr><td> 49 </td><td> 31.5 </td><td> 90.26 </td><td> 32.1 </td><td> 86.52 </td></tr><tr><td> 50 </td><td> 31.1 </td><td> 89.11 </td><td> 32.0 </td><td> 86.25 </td></tr></TBODY></TABLE>

It can be observed from the data of Table 9 that after the high oxygen water produced by the present invention is heated from the initial temperature to a high temperature, it still retains a relatively high oxygen content. For example, when the high oxygen water is heated from an initial temperature of 5 ^o C to 10 ^o C to a temperature of 40 ^o C to 50 ^o C, the oxygen content changes by less than 20%, and the oxygen content is maintained during heating. Not less than 25 ppm. In addition, after heating the initial temperature of the high-oxygen water from 5 ^o C to 10 ^o C to a temperature of 40 ^o C to 50 ^o C, the oxygen content changes preferably less than 15%, and the oxygen content is maintained during heating. Preferably it is not less than 30 ppm.

It can be seen from the above examples that the high-oxygen water of the present invention does have better stability, has a relatively high dissolved oxygen value after preparation, and passes over time and/or at a relatively high temperature (such as body temperature 37 ^o C). Under the condition, the oxygen content has a small change range, and the oxygen content is better than 25 ppm. It is not only suitable for direct drinking, but also suitable for further processing into various compositions, and is provided to the human body in various forms, for example. Intravenous injection, intravenous infusion, oral, application, etc., and not limited thereto.

In one embodiment, the hyperoxic water prepared by the foregoing method of the present invention can be prepared as a biocompatible composition comprising the hyperoxic water of the present invention and at least one biocompatible component.

Example: Pharmaceutical composition

In this embodiment, the hyperoxic water prepared by the above method of the present invention is prepared into a pharmaceutical composition, and the biocompatible component is an intravenous nutrient and/or a drug.

For example, various known intravenous nutrients may be added to the hyperoxic water prepared by the foregoing method, and the intravenous nutrient may be at least one of amino acids, fats, sugars, electrolytes, vitamins and minerals. , or a combination of two or more thereof. For example, the intravenous nutrient may be a 5% dextrose (eg, glucose) solution or a 0.9% sodium chloride solution, thereby providing a pharmaceutical composition suitable for intravenous infusion.

Further, for example, at least one type of known small molecule or macromolecular drug may be added to the hyperoxic water prepared by the above method, thereby obtaining a pharmaceutical composition for therapeutic use of the disease. The aforementioned drug is not particularly limited as long as it is suitable to exist in the form of an aqueous solution.

In one embodiment, the aforementioned small molecule drug is a drug for treating hyperuricemia, such as a xanthine oxidase inhibitor or a uric acid excretion agent. In one embodiment, the aforementioned drug for treating hyperuricemia is selected from the group consisting of allopurinol, Benzbromazone, Sulfinpyrazone, and dibesulfonamide (Probenecid), autumn. Colchicine or a combination thereof, but not limited thereto. In still another embodiment, the drug for treating hyperuricemia which can be used in combination with the hyperoxic water of the present invention means any drug which can produce an additive or synergistic effect with hyperoxic water.

Example: beverage composition

In this embodiment, the high-oxygen water prepared by the foregoing method of the present invention is prepared into a beverage composition, and the biocompatible component is any commonly used food additive, for example, such a food additive. It may be at least one of a preservative, a bactericide, an antioxidant, a nutritional additive, a flavoring agent, a sour agent, a coloring agent, a flavoring agent, a sweetener, a thickener, and an emulsifier, or a combination of any two or more thereof, and Not limited to this.

Accordingly, the aforementioned beverage composition containing the high oxygen water of the present invention can be sold in a bottled or canned form.

Example: Analysis of the effect of hyperoxic water on uric acid metabolism in animals

The Wistar strain male rats were used as experimental subjects. The rats were about 7 to 8 weeks old, weighed about 280 to 300 g, and the body weight was within 20%.

After the rats were purchased, they were observed for 2 weeks, and the experiment was carried out after the adaptation to the environment and normal growth. Control and record the temperature of the animal breeding room during the experiment is 22±3 ^o C; relative humidity 30~70%; 12 hours light/dark alternation; feed quantification, drinking water is not limited; fasting one night before administration, and administration After 4 hours, you can feed again.

In this example, 40 healthy male rats (randomized into 8 control groups, 8 control groups, 8 experimental A groups, 8 experimental B groups, and 8 experimental C groups) were used as experimental subjects.

Hyperuricemia was induced by the uric acid enzyme inhibitor oxonic acid potassium salt (purchased from Sigma-Aldrich, 0.6 g/kg/day) and uric acid (purified from Sigma-Aldrich, 0.6 g). /kg/day) as a drug for inducing hyperuricemia, the induced drug was suspended in physiological saline (0.18 g of oxonate and uric acid each suspended in 0.5 mL of physiological saline) for intraperitoneal injection. A single injection at a fixed dose (2 times/week) for 4 weeks.

The experimental groups of this example were classified as follows: Control group: 8 healthy male rats did not induce hyperuricemia, and sterilized distilled water was administered during the experiment. Control group: 8 male rats with hyperuricemia were induced by intraperitoneal injection of hyperuricemia for 4 weeks. Sterilized distilled water was given during the experiment. Group A: Eight male rats inducing hyperuricemia were intraperitoneally injected with hyperuricemia-inducing drugs for 4 weeks, and sterilized distilled water was administered during the induction period, and the hyperoxic water of the present invention was administered one week after the induction was stopped. Group B: 8 male rats with hyperuricemia induced by intraperitoneal injection of hyperuricemia induced drugs for 4 weeks, and the hyperoxic water of the present invention was administered during the induction period and 1 week after the induction was stopped. 5 weeks. Group C: 8 male rats with hyperuricemia were induced by intraperitoneal injection of hyperuricemia-inducing drug for 4 weeks, and the hyperoxic water of the present invention was administered 1 week before induction, 1 week after induction, and 1 week after induction. The high oxygen water was given for a total of 6 weeks.

The blood of each group of rats of this example was collected for uric acid value measurement during the experiment, and the results are shown in Table 10 below. Among them, the data is expressed as mean ± standard error, * represents p < 0.001 compared to the control group, and the unit of uric acid value is mg / dL. Table ten         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> days</td><td> control group</td><td> control group </ Td><td> experimental group A</td><td> experimental group B</td><td> experimental group C</td></tr><tr><td> 7 days before induction</td> <td> 0.93±0.19 </td><td> - </td><td> - </td><td> - </td><td> 0.99±0.22 </td></tr><tr ><td> Inducing Day 0</td><td> 0.93±0.19 </td><td> 1.09±0.19 </td><td> 1.1±0.19 </td><td> 1.01±0.18 </ Td><td> 1.13±0.18 </td></tr><tr><td> 7th day of induction</td><td> 0.93±0.26 </td><td> 3±0.32* </td ><td> 3.11±0.23* </td><td> 2.29±0.2* </td><td> 1.25±0.16 </td></tr><tr><td> induced day 14</td ><td> 1±0.2 </td><td> 4.13±0.39* </td><td> 4.39±0.42* </td><td> 2±0.28* </td><td> 1.5±0.23 </td></tr><tr><td> The 21st day of induction</td><td> 0.7±0.2 </td><td> 5.5±0.5* </td><td> 5.6±0.4* </td><td> 2.9±0.4* </td><td> 2.5±0.3* </td></tr><tr><td> induced day 28</td><td> 0.8±0.16 </td><td> 6.93±0.69* </td><td> 7.01±0.35* </td><td> 3.35±0.32* </td><td> 3.08±0.24* </td></ Tr></TBODY></TABLE>

From the results of Table 10, it can be observed that: (1) After the 28-day induction period, the uric acid value of the control group increased from 1.09 mg/dL to 6.93 mg/dL, and the uric acid value of the experimental group A increased from 1.1 mg/dL to 7.01. Mg/dL, and the uric acid value of the two groups on the 7th, 14th, 21st and 28th day of induction were significantly different from those in the control group; (2) After the 28-day induction period, the uric acid value of the experimental group B was only 1.01 mg. /dL increased to 3.35 mg / dL, significantly lower than the control group; (3) after the 28-day induction period, the uric acid value of the experimental group C increased only from 1.13 mg / dL to 3.08 mg / dL, significantly lower than the control group (4) The uric acid value of the experimental group C on the 7th and 14th day of induction was not significantly different from that of the control group.

On the other hand, according to the results of the above table 10, the amount of uric acid accumulation (increase) in the control group, the experimental group B and the experimental group C during the induction period was calculated, and the control group was compared with the experimental group B and the experimental group C. The uric acid accumulation amount multiple (ie, the uric acid accumulation amount in the control group divided by the uric acid accumulation amount in the experimental group B or the uric acid accumulation amount in the experimental group C), and the results are shown in Tables 11 and 12, respectively. Table XI         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> days</td><td> control group</td><td> experiment group B< /td><td> Experimental C group</td></tr><tr><td> 7th day of induction</td><td> 2.02±0.4 </td><td> 1.28±0.21 </td ><td> 0.26±0.29 </td></tr><tr><td> 14th day of induction</td><td> 3.16±0.44 </td><td> 1.01±0.34 </td>< Td> 0.51±0.27 </td></tr><tr><td> induction day 21</td><td> 4.46±0.49 </td><td> 1.91±0.26 </td><td> 1.5±0.39 </td></tr><tr><td> 28th day of induction</td><td> 5.87±0.58 </td><td> 2.34±0.43 </td><td> 2.09± 0.33 </td></tr></TBODY></TABLE> Table 12         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> days</td><td> control group accumulation/experiment B group accumulation amount</td ><td> Control group accumulation amount/Experiment C group accumulation amount</td></tr><tr><td> Induction 7th day</td><td> 1.58 times</td><td> 7.77 times </td></tr><tr><td> Inducing the 14th day</td><td> 3.13 times</td><td> 6.2 times</td></tr><tr><td> Inducing the 21st day</td><td> 2.34 times</td><td> 2.97 times</td></tr><tr><td> Inducing the 28th day</td><td> 2.51 times< /td><td> 2.81 times</td></tr></TBODY></TABLE>

The foregoing results demonstrate that the hyperoxic water of the present invention not only has an effect of preventing hyperuricemia, but also has an effect of treating hyperuricemia.

In addition, after the induction of hyperuricemia in each experimental group for 4 weeks, the control group and the control group were provided with sterilized distilled water for 1 week, and the experimental group A, the experimental group B and the experimental group C were provided with the high-oxygen water of the invention for 1 week. The uric acid value changes were continuously observed, and the results are shown in Table 13 below, wherein the first day after the induction was stopped on the 29th day, the third day after the induction was stopped on the 31st day, and so on. Table thirteen         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> days</td><td> control group</td><td> control group </ Td><td> experimental group A</td><td> experimental group B</td><td> experimental group C</td></tr><tr><td> induced day 28</td> <td> 0.8±0.16 </td><td> 6.93±0.69* </td><td> 7.01±0.35* </td><td> 3.35±0.32* </td><td> 3.08±0.24* </td></tr><tr><td> Day 29 of induction</td><td> 0.9±0.2 </td><td> 6.2±0.4* </td><td> 5.5±0.3* </td><td> 2.1±0.1* </td><td> 1.8±0.2* </td></tr><tr><td> 31st day of induction</td><td> 1.1±0.2 </td><td> 5.4±0.3* </td><td> 2.9±0.4* </td><td> 1.3±0.2 </td><td> 1.1±0.2 </td></tr> <tr><td> Inducing the 33rd day</td><td> 0.9±0.3 </td><td> 3.95±0.2* </td><td> 1.05±0.2 </td><td> 0.8± 0.2 </td><td> 0.8±0.3 </td></tr><tr><td> 35th day of induction</td><td> 1.1±0.2 </td><td> 2.2±0.2* </td><td> 0.96±0.2 </td><td> 0.9±0.2 </td><td> 1±0.2 </td></tr></TBODY></TABLE>

From the above data, it can be found that: (1) On the 7th day after the induction of the control group, the uric acid value (2.2 mg/dL) was still significantly higher than that of the control group; (2) all the experimental groups were stopped after the induction of the first and third, The uric acid value of 5 and 7 days was significantly lower than that of the control group. (3) On the 5th day after the induction of group A, the uric acid value (1.05 mg/dL) returned to the normal range and remained in the normal range. (4) On the third day after the induction of the experimental group B and the experimental group C, the uric acid value (1.3 mg/dL, 1.1 mg/dL) returned to the normal range and remained within the normal range.

On the other hand, according to the results of Table 13 above, the amount of uric acid excretion (decrease) in the control group and the experimental group A after stopping the induction and the excretion (reduction) of the experimental group A compared with the control group were calculated. As shown in Table XIV. Table fourteen         <TABLE border="1" borderColor="#000000" width="85%"><TBODY><tr><td> days</td><td> reduction in control group</td><td> experiment A Group reduction </td><td> reduction in experimental group A/reduction in control group</td></tr><tr><td> induction on day 29</td><td> -0.74±0.93 < /td><td> -1.56±0.43 </td><td> 2.11 times</td></tr><tr><td> 31st day of induction</td><td> -1.56±0.6 </ Td><td> -4.14±0.57 </td><td> 2.65 times</td></tr><tr><td> induced day 33</td><td> -2.98±0.69 </td ><td> -5.86±0.31 </td><td> 2 times</td></tr><tr><td> induced 35th day</td><td> -4.73±0.63 </td> <td> -6.05±0.42 </td><td> 1.28 times</td></tr></TBODY></TABLE>

The foregoing results demonstrate that the hyperoxic water of the present invention can promote the excretion of uric acid in the body and has a therapeutic effect on hyperuricemia.

The above embodiments are merely illustrative in nature and are not intended to limit the application or the application or use of the embodiments. As used herein, the term "exemplary" means "as an example, instance or description." Unless otherwise indicated, any of the exemplary embodiments herein are not necessarily to be construed as preferred or preferred.

In addition, while at least one exemplary embodiment has been presented in the foregoing embodiments, it should be understood that a It should also be understood that the embodiments described herein are not intended to limit the scope, use, or configuration of the claimed application. Conversely, the foregoing embodiments may provide one or more embodiments of the invention in the form of the invention. Furthermore, the scope of the patent application includes the known equivalents and all foreseeable equivalents in the application of the present application.

Claims (11)

A use of high oxygen water for preparing a medicament for treating and/or preventing hyperuricemia, wherein the hyperoxic water is allowed to stand for 30 minutes after the initial oxygen content of the hyperoxic water is 100% The difference (AB) between the oxygen percentage (A) and the oxygen content percentage (B) after the high oxygen water is allowed to stand for 180 minutes is less than 24%, and the high oxygen water is at 30 ° C to 40 ° C. After 120 minutes of maintenance, the oxygen content was between 20 ppm and 60 ppm. The use of claim 1 wherein the difference is less than 15%. The use according to claim 1, wherein the high oxygen water has a full width at half maximum between 40 Hz and 80 Hz as measured by ¹⁷ O NMR. The use of claim 1, wherein the high oxygen water has an oxygen content between 20 ppm and 50 ppm after the high oxygen water is maintained at 30 ° C to 40 ° C for 120 minutes. The use according to claim 1, wherein the oxygen content changes by less than 20% after heating the high oxygen water from 10 ° C to 40 ° C. The use according to claim 1, wherein the oxygen-containing amount is changed by less than 25% after the high-oxygen water is maintained at 30 ° C to 40 ° C for 120 minutes. The use according to claim 1, wherein the oxygen-containing water has a change in oxygen content of less than 20% after heating the initial temperature of the high-oxygen water from 5 ° C to 10 ° C to a temperature of from 40 ° C to 50 ° C. The use of claim 1, wherein the high oxygen water system is composed of water, oxygen, and non-human addition components. The use according to claim 1, wherein the high-oxygen water system is prepared by supplying oxygen to a water body and maintaining the water body at 4 ° C to 8 ° C during oxygen supply. Under the condition, oxygen is supplied to the water at a flow rate of 50 cc/min to 1000 cc/min, and the oxygen supply time is not less than 30 minutes. The use according to claim 1, wherein the hyperoxic water is present in the form of a pharmaceutical composition, and the pharmaceutical composition is provided to a recipient having hyperuricemia by oral, intravenous or intravenous infusion. The use of claim 10, wherein the pharmaceutical composition further comprises at least one drug for treating hyperuricemia.